<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">scbmt</journal-id><journal-title-group><journal-title xml:lang="ru">БИОМЕДИЦИНА</journal-title><trans-title-group xml:lang="en"><trans-title>Journal Biomed</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2074-5982</issn><issn pub-type="epub">2713-0428</issn><publisher><publisher-name>Scientific center of biomedical technologies of Federal Medical and Biological Agency</publisher-name></publisher></journal-meta><article-meta><article-id custom-type="elpub" pub-id-type="custom">scbmt-1167</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ФАРМАКОГЕНЕТИКА</subject></subj-group></article-categories><title-group><article-title>Полиморфизм генов системы детоксикации ксенобиотиков и его роль в биотрансформации внутривенных анестетиков</article-title><trans-title-group xml:lang="en"><trans-title>Polymorphism genes of the system xenobiotics detoxycation and its role in biotransformation of intravenous anaesthetics</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Махарин</surname><given-names>О. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Maharin</surname><given-names>O. A.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Макляков</surname><given-names>Ю. С.</given-names></name><name name-style="western" xml:lang="en"><surname>S Maklyakov</surname><given-names>Y. .</given-names></name></name-alternatives><email xlink:type="simple">Miv1010@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Женило</surname><given-names>В. М.</given-names></name><name name-style="western" xml:lang="en"><surname>Genilo</surname><given-names>V. M.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru">Ростовский государственный медицинский университет, Ростов-на-Дону<country>Россия</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2012</year></pub-date><pub-date pub-type="epub"><day>18</day><month>02</month><year>2020</year></pub-date><volume>1</volume><issue>3</issue><fpage>98</fpage><lpage>107</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Махарин О.А., Макляков Ю.С., Женило В.М., 2020</copyright-statement><copyright-year>2020</copyright-year><copyright-holder xml:lang="ru">Махарин О.А., Макляков Ю.С., Женило В.М.</copyright-holder><copyright-holder xml:lang="en">Maharin O.A., S Maklyakov Y..., Genilo V.M.</copyright-holder><license license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://journal.scbmt.ru/jour/article/view/1167">https://journal.scbmt.ru/jour/article/view/1167</self-uri><trans-abstract xml:lang="en"><p>Despite of wide arsenal of drugs for narcosis, existing now, quite often the anaesthesiologist is faced with the problem of optimum diagram of anaesthesia. Evaluation age, social, emotional characteristics of patient is often not enough. That is why studying SNP-polymorphisms and their influence on a metabolism of anaesthetics, probably will allow to optimize the concept of «individual approach» in anaesthesiologia. A substantial part of the individual variability of person response to drugs is related with single nucleotides polymorphisms. Drugs that are used in general anesthesia undergo polymorphic metabolism. Among these, CYP2B6, CYP3A4 and CYP2C9 play a relevant role in the metabolism of ketamine. The enzymes involved in the metabolism of thiopental are still unknown. Propofol is metabolized mainly by glucuronidation by uridine diphosphate-glucuronosyltransferases (UGTs) and by hydroxylation by CYP2B6 and CYP2C enzymes. The enzymes SULT1A1 and NQO1 participate in later steps in propofol metabolism. CYP3A4, CYP3A5, CYP2B6, CYP2C19 play significant role in later steps in propofol metabolism. CYP3A4, CYP3A5, CYP2B6, CYP2C19 play significant role in the metabolism of benzodiazepines. The present review analyses the importance of enzymes in the metabolism of anaesthetics.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>pharmacogenetics</kwd><kwd>intravenous anaesthesia</kwd><kwd>biotransformation</kwd><kwd>polymorphisms</kwd><kwd>allele</kwd><kwd>cytochromes</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Волчков В.А., Игнатов Ю.Д., Страшнов В.И. Болевые синдромы в анестезиологии и реаниматологии – М.: МЕДпресс-информ. 2006.</mixed-citation><mixed-citation xml:lang="en">Волчков В.А., Игнатов Ю.Д., Страшнов В.И. Болевые синдромы в анестезиологии и реаниматологии – М.: МЕДпресс-информ. 2006.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Каркищенко Н.Н. Основы биомоделирования – М.: Межакадемическое издательство ВПК. 2004.</mixed-citation><mixed-citation xml:lang="en">Каркищенко Н.Н. Основы биомоделирования – М.: Межакадемическое издательство ВПК. 2004.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Кукес В.Г., Грачев С.В., Сычев Д.А., Раменская Г.В. Метаболизм лекарственных средств, научные основы персонализированной медицины М.: ГЕ- ОТАР-Медиа. 2008.</mixed-citation><mixed-citation xml:lang="en">Кукес В.Г., Грачев С.В., Сычев Д.А., Раменская Г.В. Метаболизм лекарственных средств, научные основы персонализированной медицины М.: ГЕ- ОТАР-Медиа. 2008.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Сарвилина И.В., Каркищенко В.Н., Горшкова Ю.В. Мир биологии и медицины. Междиссиплинарные исследования в медицине – М.: ТЕХНОСФЕ- РА. 2007.</mixed-citation><mixed-citation xml:lang="en">Сарвилина И.В., Каркищенко В.Н., Горшкова Ю.В. Мир биологии и медицины. Междиссиплинарные исследования в медицине – М.: ТЕХНОСФЕ- РА. 2007.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Симон В.А. Цитохром Р-450 и взаимодействие лекарственных веществ / Материалы VII Российской конференции «Гепатология сегодня». 2002.</mixed-citation><mixed-citation xml:lang="en">Симон В.А. Цитохром Р-450 и взаимодействие лекарственных веществ / Материалы VII Российской конференции «Гепатология сегодня». 2002.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Сычев Д.А. Клиническая фармакогенетика. Клиническая фармакология / под ред. акад. РАМН, проф. Кукеса В.Г. – М.: ГЕОТАР-Медиа. 2004.</mixed-citation><mixed-citation xml:lang="en">Сычев Д.А. Клиническая фармакогенетика. Клиническая фармакология / под ред. акад. РАМН, проф. Кукеса В.Г. – М.: ГЕОТАР-Медиа. 2004.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Carlos Isaza; Julieta Henao Jose; H Isaza Martinez, Juan C. Sepulveda Arias, Leonardo Beltran. Phenotype-genotype analysis of CYP2C19 in Colombian mestizo individuals. BMC Clin Pharmacol. 2007; 7:6.</mixed-citation><mixed-citation xml:lang="en">Carlos Isaza; Julieta Henao Jose; H Isaza Martinez, Juan C. Sepulveda Arias, Leonardo Beltran. Phenotype-genotype analysis of CYP2C19 in Colombian mestizo individuals. BMC Clin Pharmacol. 2007; 7:6.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Cheng J.T., Chen R.M. Mechanisms of ketamine-involved regulation of cytochrome P450 gene expression. Expert Opin Drug Metab Toxicol. 2010. Mar; 6(3): 273-81.</mixed-citation><mixed-citation xml:lang="en">Cheng J.T., Chen R.M. Mechanisms of ketamine-involved regulation of cytochrome P450 gene expression. Expert Opin Drug Metab Toxicol. 2010. Mar; 6(3): 273-81.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Chorley B. N, Wang X., Campbell M. R., Pittman G.S., Noureddine M.A. Bell D.A. Discovery and verification of functional single nucleotide polymorphisms in regulatory genomic regions: current developing technologics. Mutat. Res. 2008; 659: 147-157.</mixed-citation><mixed-citation xml:lang="en">Chorley B. N, Wang X., Campbell M. R., Pittman G.S., Noureddine M.A. Bell D.A. Discovery and verification of functional single nucleotide polymorphisms in regulatory genomic regions: current developing technologics. Mutat. Res. 2008; 659: 147-157.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Crettol S., Petrovic N., Murray M. Pharmacogenetics of phase 1 and phase 2 drug metabolism. Curr. Pharm. Des. 2010. 16(2); 204-16.</mixed-citation><mixed-citation xml:lang="en">Crettol S., Petrovic N., Murray M. Pharmacogenetics of phase 1 and phase 2 drug metabolism. Curr. Pharm. Des. 2010. 16(2); 204-16.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Daly A.K. Significance of the minor cytochrome P450 3A isoforms. Clin Pharmacokinet. 45(1):13-31; 2006.</mixed-citation><mixed-citation xml:lang="en">Daly A.K. Significance of the minor cytochrome P450 3A isoforms. Clin Pharmacokinet. 45(1):13-31; 2006.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Desta Z, Xu C., Oqburn E.T., Guo Y. Effects of the CYP2B6*6 allele on catalytic properties and inhibition of CYP B6 in vitro: implication for the mechanism of reduced efavirenz metabolism and other CYP 2 B6 substrates in vivo. Drug Metab Dispos. 2012. 9.</mixed-citation><mixed-citation xml:lang="en">Desta Z, Xu C., Oqburn E.T., Guo Y. Effects of the CYP2B6*6 allele on catalytic properties and inhibition of CYP B6 in vitro: implication for the mechanism of reduced efavirenz metabolism and other CYP 2 B6 substrates in vivo. Drug Metab Dispos. 2012. 9.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Evans W.E., Johnson J.A. Pharmacogenomics: the inherited basis for interindividual differences in drug response. 2001.</mixed-citation><mixed-citation xml:lang="en">Evans W.E., Johnson J.A. Pharmacogenomics: the inherited basis for interindividual differences in drug response. 2001.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Fowler S.M., Riley R.S., Pritchard M.P.,Sutelitte M.S., Friedberg T., Wolf C.R. Amino acid 305 determines catalytic center accessibility in CYP3A4. Biochemistry. 18; 39(15):4406-14. 2000.</mixed-citation><mixed-citation xml:lang="en">Fowler S.M., Riley R.S., Pritchard M.P.,Sutelitte M.S., Friedberg T., Wolf C.R. Amino acid 305 determines catalytic center accessibility in CYP3A4. Biochemistry. 18; 39(15):4406-14. 2000.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Garfinkel D. Studies on pig liver microsomes. I. Enzimic and pigment composition of different microsomal fractions. Arch Biochem. Biophys. 1958. 77. 493-509.</mixed-citation><mixed-citation xml:lang="en">Garfinkel D. Studies on pig liver microsomes. I. Enzimic and pigment composition of different microsomal fractions. Arch Biochem. Biophys. 1958. 77. 493-509.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Inomata S., Nagashima A., Itagaki F., Homma M., Nishimura M., Osaka Y., Okuyama K., Tanaka E., Nakamura T., Kohda Y., Naito S., Miyabe M., Toyooka H. CYP2C19 genotype affects diazepam pharmacokinetics and emergence from general anesthesia. Clin Pharmacol Ther. 2005 Dec;78(6):647-55.</mixed-citation><mixed-citation xml:lang="en">Inomata S., Nagashima A., Itagaki F., Homma M., Nishimura M., Osaka Y., Okuyama K., Tanaka E., Nakamura T., Kohda Y., Naito S., Miyabe M., Toyooka H. CYP2C19 genotype affects diazepam pharmacokinetics and emergence from general anesthesia. Clin Pharmacol Ther. 2005 Dec;78(6):647-55.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Ingelmen-Sundberg M. The human genome project and novel aspects of cytochrome P450 research. Toxicol. Appl. Pharmacol. 2005. 207: 52-56.</mixed-citation><mixed-citation xml:lang="en">Ingelmen-Sundberg M. The human genome project and novel aspects of cytochrome P450 research. Toxicol. Appl. Pharmacol. 2005. 207: 52-56.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Kalow W., Tang B.K., Endrenyi T. Hypothesis: comparisons of inter- and intrainvolved variations can substitute for twin studies in drug research. Pharmacogenetics 1998; 8:283-289.</mixed-citation><mixed-citation xml:lang="en">Kalow W., Tang B.K., Endrenyi T. Hypothesis: comparisons of inter- and intrainvolved variations can substitute for twin studies in drug research. Pharmacogenetics 1998; 8:283-289.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Klingenberg M. Pigments of rat liver microsomes. Arch Biochem. Biophys., 1958. 75. 376-386.</mixed-citation><mixed-citation xml:lang="en">Klingenberg M. Pigments of rat liver microsomes. Arch Biochem. Biophys., 1958. 75. 376-386.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Khokhar J.Y., Tyndale R.F. Drug metabolism within the brain changes drug response: selective manipulation of brain CYP2B alters propofol effects. Neuropsychopharmacology. 2011. Feb. 36(3): 692-700.</mixed-citation><mixed-citation xml:lang="en">Khokhar J.Y., Tyndale R.F. Drug metabolism within the brain changes drug response: selective manipulation of brain CYP2B alters propofol effects. Neuropsychopharmacology. 2011. Feb. 36(3): 692-700.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Lamba J.K., Lin Y.S., Schuetz E.G., Thummel K.E. Genetic contribution to variable human CYP3A-mediated metabolism. Adv Drug Devil Rev. 2002. Nov 18. 54(10): 1271-94.</mixed-citation><mixed-citation xml:lang="en">Lamba J.K., Lin Y.S., Schuetz E.G., Thummel K.E. Genetic contribution to variable human CYP3A-mediated metabolism. Adv Drug Devil Rev. 2002. Nov 18. 54(10): 1271-94.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Lee S.J., Goldstein J.A. Functinally defective or altered CYP3A4 and CYP3A5 single nucleotide polymorphisms and their with genotyping tests. Pharmacogenomics. 2005. Jun; 6(4): 357-71.</mixed-citation><mixed-citation xml:lang="en">Lee S.J., Goldstein J.A. Functinally defective or altered CYP3A4 and CYP3A5 single nucleotide polymorphisms and their with genotyping tests. Pharmacogenomics. 2005. Jun; 6(4): 357-71.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Mo S.L., Liu Y.H., Duan W., Wei M.Q., Kanwar J.R., Zhou S.F. Substrate specificity, regulation, and polymorphism of human cytochrome P450 2B6. Curr Drug Metab. 2009. Sep; 10(7):730-53.</mixed-citation><mixed-citation xml:lang="en">Mo S.L., Liu Y.H., Duan W., Wei M.Q., Kanwar J.R., Zhou S.F. Substrate specificity, regulation, and polymorphism of human cytochrome P450 2B6. Curr Drug Metab. 2009. Sep; 10(7):730-53.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Mossner L.D., Schmitz A., Theurillat R., Thormann W., Mevissen M. Inhibition of cytochrome P450 enzymes involved in ketamine metabolism by use of liver microsomes and specific cytochrome P450 enzymes from horses, dogs and humans. Am J. Vet Res. 2011. Nov; 72(11): 1505-13.</mixed-citation><mixed-citation xml:lang="en">Mossner L.D., Schmitz A., Theurillat R., Thormann W., Mevissen M. Inhibition of cytochrome P450 enzymes involved in ketamine metabolism by use of liver microsomes and specific cytochrome P450 enzymes from horses, dogs and humans. Am J. Vet Res. 2011. Nov; 72(11): 1505-13.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Noppers I., Olofsen E., Niesters M., Aarts L., Mooren R., Dahan A., Kharasch E., Sarton E. Effect of rifampicin on S-ketamine and S-norketamine plasma concentrations in healthy volunteers after intravenous S-ketamine administration. Anesthesiology. 2011. Jun; 114(6): 1435-45.</mixed-citation><mixed-citation xml:lang="en">Noppers I., Olofsen E., Niesters M., Aarts L., Mooren R., Dahan A., Kharasch E., Sarton E. Effect of rifampicin on S-ketamine and S-norketamine plasma concentrations in healthy volunteers after intravenous S-ketamine administration. Anesthesiology. 2011. Jun; 114(6): 1435-45.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Ogawa R., Echizen H. Drugdrug interaction profiles of proton pump inhubitors. Clin. Pharmacokinet. 2010. Aug; 49(8): 509-33.</mixed-citation><mixed-citation xml:lang="en">Ogawa R., Echizen H. Drugdrug interaction profiles of proton pump inhubitors. Clin. Pharmacokinet. 2010. Aug; 49(8): 509-33.</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Okkola K.T., Ahonen S. Midazolam and other benzodiazepines. Handb Exp Pharmacol. 2008. (182): 335-60.</mixed-citation><mixed-citation xml:lang="en">Okkola K.T., Ahonen S. Midazolam and other benzodiazepines. Handb Exp Pharmacol. 2008. (182): 335-60.</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Omura, T., Sato, R., Cooper, D.Y., Rosenthal, O., and Estebrook, K.W. Function of cytochrome P450 microsomes. Fed. Pron. 1965. 24. 1181-1189.</mixed-citation><mixed-citation xml:lang="en">Omura, T., Sato, R., Cooper, D.Y., Rosenthal, O., and Estebrook, K.W. Function of cytochrome P450 microsomes. Fed. Pron. 1965. 24. 1181-1189.</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Osaka Y., Inomata S., Tanaka E., Nakamura T., Honda K., Miyabe M., Toyooka H., Tanaka M. Effect of propofol on ropivacaine metabolism in human liver microsomes. J. Anesth. 2006. 20(1):60-3.</mixed-citation><mixed-citation xml:lang="en">Osaka Y., Inomata S., Tanaka E., Nakamura T., Honda K., Miyabe M., Toyooka H., Tanaka M. Effect of propofol on ropivacaine metabolism in human liver microsomes. J. Anesth. 2006. 20(1):60-3.</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Peltonieni M.A., Saari T.I., Hagelberg N.M., Reponen P, Turpeinen M., Laine K., Neuvonen P.J., Olkkola K.T. Exposure to oral S-ketamine is unaffected by itraconazole but greatly increased by ticlopidine. Clin Pharmacol Ther, 2011.</mixed-citation><mixed-citation xml:lang="en">Peltonieni M.A., Saari T.I., Hagelberg N.M., Reponen P, Turpeinen M., Laine K., Neuvonen P.J., Olkkola K.T. Exposure to oral S-ketamine is unaffected by itraconazole but greatly increased by ticlopidine. Clin Pharmacol Ther, 2011.</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Phillips K.A., Veenstra D.L., Oren E. et al. Potential role of pharmacogenomics in reducing adverse drug reactions: a systematic review. J.A.M.A. 2001. 286: 2270-2279.</mixed-citation><mixed-citation xml:lang="en">Phillips K.A., Veenstra D.L., Oren E. et al. Potential role of pharmacogenomics in reducing adverse drug reactions: a systematic review. J.A.M.A. 2001. 286: 2270-2279.</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Restrepo J.G., Garcia-Martin I., Martinez C. et al. Polimorphic drug metabolism in anaesthesia. Curr Drug Metab. 2009. Mar; 10(3): 236-46.</mixed-citation><mixed-citation xml:lang="en">Restrepo J.G., Garcia-Martin I., Martinez C. et al. Polimorphic drug metabolism in anaesthesia. Curr Drug Metab. 2009. Mar; 10(3): 236-46.</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Restrepo J.G., Martinez C., Garcia-Agurdez A. et al. Cytochrome P450 CYP2B6 genotypes and haplotypes in a colombian population: identification of novel variant CYP2B6 alleles. Pharmacogenet Genomics 2011. 21. 773-8.</mixed-citation><mixed-citation xml:lang="en">Restrepo J.G., Martinez C., Garcia-Agurdez A. et al. Cytochrome P450 CYP2B6 genotypes and haplotypes in a colombian population: identification of novel variant CYP2B6 alleles. Pharmacogenet Genomics 2011. 21. 773-8.</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru">Sugimoto M., Futura T., Nakamura A., Shirai N., Ikuma M., Misaka S., Uchida S., Watanabe H., Ohashi K., Ishizaki T., Hishida A. Maintenance time of sedative effects after an intravenous infusion of diazepam: a guide for endoscopy using diazepam. World J. Gastroenterol. 2008. Sep 7;14(33): 5197-203.</mixed-citation><mixed-citation xml:lang="en">Sugimoto M., Futura T., Nakamura A., Shirai N., Ikuma M., Misaka S., Uchida S., Watanabe H., Ohashi K., Ishizaki T., Hishida A. Maintenance time of sedative effects after an intravenous infusion of diazepam: a guide for endoscopy using diazepam. World J. Gastroenterol. 2008. Sep 7;14(33): 5197-203.</mixed-citation></citation-alternatives></ref><ref id="cit35"><label>35</label><citation-alternatives><mixed-citation xml:lang="ru">Yanagihara Y., Kariga S., Ohtani M., Uchino K., Aogama T., Yamamura Y. Involvement of CYP2B6 in n-demethylation of ketamine in human liver microsomes. 2008.</mixed-citation><mixed-citation xml:lang="en">Yanagihara Y., Kariga S., Ohtani M., Uchino K., Aogama T., Yamamura Y. Involvement of CYP2B6 in n-demethylation of ketamine in human liver microsomes. 2008.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
